COMPLEX TREATMENT OF DIARRHEA IN CHILDREN

The article presents modern data on syndrome of acute diarrhea in children, its etiology and mechanisms of development of different types of this disease, its clinical symptoms, differential diagnosis, laboratory and instrumental methods of diagnostics. Author gives review of pathogenetic treatment and opportunities of therapy with enterosorbates, taking into account etiology of diarrhea. Another chapter of the article describes opportunities and methods of oral hydration depending of extent of exicosis. Key words: acute diarrhea, children, etiology, pathogenesis, clinical symptoms, etiotropic therapy, enterosorbates, oral hydration.(Voprosy sovremennoi pediatrii — Current Pediatrics. 2010;9(5):111-1116

CLINICAL EXAMPLES OF ANTICYTOKINE TREATMENT OF CHILDREN WITH CROHN DISEASE

Infliximab is one of the first biological agents that has proven its efficacy in Crohn’s disease treatment in various multicenter randomized studies. Anticytokine treatment with infliximab allows to reach clinical, lab and endoscopic remission and secure its maintenance. This article contains clinical examples of anticytokine therpy with infliximab (Remikeid) efficacy in children with Crohn’s disease. Key words: Crohn’s disease, children, anticytokine therapy, infliximab. (Voprosy sovremennoi pediatrii — Current Pediatrics. — 2011; 10 (5): 74–80.

ANTI-CYTOKINE THERAPY FOR CHILDREN WITH INFLAMMATORY BOWEL DISEASES

The article describes the findings of a pilot research devoted to the estimation of the efficiency of a therapy with TNF α inhibitors for children with inflammatory bowel diseases. Methods: we carried out the retrospective analysis for a therapy with Infliximab in 15 children with a nonspecific ulcerative colitis and Сrohn's disease. Results: 66% of the children with inflammatory bowel diseases react to the first injection of Infliximab, whereas 13% of the children demonstrate a clinical remission of their diseases. After the third injection, a positive response to the used therapy is shown by 60% of the children with inflammatory bowel diseases, and 33% of the children are diagnosed with a clinical remission. Conclusion: The use of Infliximab allowed the children with a refractory course of nonspecific ulcerative colitis and Сrohn's disease to make their inflammation significantly less active and improve the quality of their life.Key words: nonspecific ulcerative colitis, Сrohn's disease, treatment, TNF α inhibitors, childre

APPLICATION EXPERIENCE OF THE ENTERAL FEEDING IN A PATIENT WITH THE STENOSING FORM OF CROHN'S DISEASE

The article describes the rare form of crohn's disease acquired by a child with the localization in the pre pyloric stomach section and steno sing complications. Due to the development of the acute bowel obstruction, the girl underwent a surgery. taking into account her young age, hypotrophy, low activity of inflammation as well as the inability of the peroral administration of the anti inflammatory medications during the postoperative period, the girl was prescribed full enteral feeding with modulen IBD medical mixture for the patients suffering from the inflammatory intestinal diseases against which the doctors noted the positive clinical and laboratory dynamics.Key words: crohn's disease, enteral feeding, children

APPLICATION EXPERIENCE OF THE ENTERAL FEEDING IN A PATIENT WITH THE STENOSING FORM OF CROHN'S DISEASE

The article describes the rare form of crohn's disease acquired by a child with the localization in the pre pyloric stomach section and steno sing complications. Due to the development of the acute bowel obstruction, the girl underwent a surgery. taking into account her young age, hypotrophy, low activity of inflammation as well as the inability of the peroral administration of the anti inflammatory medications during the postoperative period, the girl was prescribed full enteral feeding with modulen IBD medical mixture for the patients suffering from the inflammatory intestinal diseases against which the doctors noted the positive clinical and laboratory dynamics.Key words: crohn's disease, enteral feeding, children

MARKERS OF THE ENTERIC INFLAMMATION IN THE EVENT OF INTESTINAL DISEASES: LITERATURE REVIEW

The authors provided modern information on the basic noninvasive methods to assess the inflammatory process in the intestine in crohn's disease and colitis gravis. The researchers thoroughly described the opportunities and limitations for the use of faecal calprotectin as a marker of the inflammatory enteric diseases. Importance of this marker for the differential diagnostics of  the inflammatory and functional enteric diseases has been shown.Key words: markers of the enteric inflammation, faecal calprotectin, inflammatory bowel diseases, colitis gravis, сrohn's disease

FAECAL CALPROTECTIN IN NONINVASIVE DIAGNOSTICS OF THE INFLAMMATORY ENTERIC DISEASES AMONG CHILDREN

The authors studied the opportunities to define the level of faecal calprotectin in diagnostics of the inflammatory enteric diseases (grohn's disease and colitis gravis) among children. It was established that children, suffering from the inflammatory enteric diseases, the concentration of faecal calprotectin increases, thus, correlating with the clinical and endoscopic activity of the disease, as well as with the spread of the intestinal impairment. Faecal calprotectin may be a reliable marker of the inflammation activity in the event of grohn's disease and colitis gravis.Key words: faecal calprotectin, inflammatory enteric diseases, colitis gravis, grohn's disease, diagnostics, children

АНТИЦИТОКИНОВАЯ ТЕРАПИЯ У ДЕТЕЙ С ВОСПАЛИТЕЛЬНЫМИ ЗАБОЛЕВАНИЯМИ КИШЕЧНИКА

The article describes the findings of a pilot research devoted to the estimation of the efficiency of a therapy with TNF α inhibitors for children with inflammatory bowel diseases. Methods: we carried out the retrospective analysis for a therapy with Infliximab in 15 children with a nonspecific ulcerative colitis and Сrohn's disease. Results: 66% of the children with inflammatory bowel diseases react to the first injection of Infliximab, whereas 13% of the children demonstrate a clinical remission of their diseases. After the third injection, a positive response to the used therapy is shown by 60% of the children with inflammatory bowel diseases, and 33% of the children are diagnosed with a clinical remission. Conclusion: The use of Infliximab allowed the children with a refractory course of nonspecific ulcerative colitis and Сrohn's disease to make their inflammation significantly less active and improve the quality of their life.Key words: nonspecific ulcerative colitis, Сrohn's disease, treatment, TNF α inhibitors, childrenВ статье отражены данные пилотного исследования эффективности терапии ингибиторами ФНО α у детей с воспалительными заболеваниями кишечника. Методы: проведен ретроспективный анализ терапии инфликсимабом у 15 детей с неспецифическим язвенным колитом и болезнью Крона. Результаты: 66% детей с ВЗК отвечают на первое введение Ремикейда, и у 13% детей наблюдается клиническая ремиссия заболеваний. После третьего введения положительный ответ на проводимую терапию наблюдается у 60% детей с ВЗК, у 33% детей была диагностирована клиническая ремиссия. Заключение: Применение инфликсимаба позволило детям с рефрактерным течением НЯК и БК значительно снизить активность воспаления и улучшить качество жизни. Ключевые слова: неспецифический язвенный колит, болезнь Крона, лечение, ингибиторы ФНО α, дети. (Педиатрическая фармакология. – 2009; 6(1):23-29)

FAECAL CALPROTECTIN IN NONINVASIVE DIAGNOSTICS OF THE INFLAMMATORY ENTERIC DISEASES AMONG CHILDREN

The authors studied the opportunities to define the level of faecal calprotectin in diagnostics of the inflammatory enteric diseases (grohn's disease and colitis gravis) among children. It was established that children, suffering from the inflammatory enteric diseases, the concentration of faecal calprotectin increases, thus, correlating with the clinical and endoscopic activity of the disease, as well as with the spread of the intestinal impairment. Faecal calprotectin may be a reliable marker of the inflammation activity in the event of grohn's disease and colitis gravis.Key words: faecal calprotectin, inflammatory enteric diseases, colitis gravis, grohn's disease, diagnostics, children

MARKERS OF THE ENTERIC INFLAMMATION IN THE EVENT OF INTESTINAL DISEASES: LITERATURE REVIEW

The authors provided modern information on the basic noninvasive methods to assess the inflammatory process in the intestine in crohn's disease and colitis gravis. The researchers thoroughly described the opportunities and limitations for the use of faecal calprotectin as a marker of the inflammatory enteric diseases. Importance of this marker for the differential diagnostics of  the inflammatory and functional enteric diseases has been shown.Key words: markers of the enteric inflammation, faecal calprotectin, inflammatory bowel diseases, colitis gravis, сrohn's disease